Bio-Techne Corporation Bio-Techne Corporation

Bio-Techne Corporation

TECH

Pozycja w akcjach #1869
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Cena akcji
$72.50
Kapitalizacja rynkowa
$11.37B
Zmiana (1 dzień)
-0.10%
Zmiana (1 rok)
17.20%
Kraj
US
Handel Bio-Techne Corporation (TECH)

Kategoria

Healthcare
Przychody dla Bio-Techne Corporation (TECH)
Przychody w Jun 2026 TTM: $1.22B
Według najnowszych raportów finansowych Bio-Techne Corporation, obecny przychód firmy (TTM) wynosi $1.22B. W roku 2024 firma osiągnęła przychód w wysokości $1.16B wzrost w porównaniu do przychodu z roku 2023, który wynosił $1.14B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Bio-Techne Corporation od 2000 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $1.22B -0.38%
2025 $1.22B 5.23%
2024 $1.16B 1.97%
2023 $1.14B 2.81%
2022 $1.11B 18.75%
2021 $931.03M 26.04%
2020 $738.69M 3.46%
2019 $714.01M 11.04%
2018 $642.99M 14.21%
2017 $563.00M 12.82%
2016 $499.02M 10.34%
2015 $452.25M 26.41%
2014 $357.76M 15.19%
2013 $310.58M -1.27%
2012 $314.56M 8.48%
2011 $289.96M 7.77%
2010 $269.05M 1.93%
2009 $263.96M 2.54%
2008 $257.42M 15.19%
2007 $223.48M 10.30%
2006 $202.62M 13.41%
2005 $178.65M 10.79%
2004 $161.26M 11.20%
2003 $145.01M 10.78%
2002 $130.90M 13.47%
2001 $115.36M 11.09%
2000 $103.84M 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
$12.62B 939.00%
US
$2.23B 83.37%
US
$15.74B 1,195.79%
AU
- -
CH
$6.02B 395.56%
NL